personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

The association of interleukin-8 promoter polymorphism -251 A/T to the initial bevacizumab treatment response in age-related macular degeneration

Session Details

Session Title: AMD I

Session Date/Time: Thursday 26/09/2013 | 08:30-10:30

Paper Time: 09:10

Venue: Hall 1 (Level 2)

First Author: A.Hautamaki FINLAND

Co Author(s):    J. Kivioja   S. Vavuli   M. Liinamaa   P. Onkamo     

Abstract Details

Purpose:

The study was conducted to evaluate the association of single nucleotide polymorphisms (SNPs) of interleukin-8 (IL-8), vascular endothelial growth factor, erythropoietin, complement factor H, complement component C3, and LOC387715 genes with the response to bevacizumab-treatment in exudative age-related macular degeneration (AMD).

Setting:

The medical records of patients with exudative AMD receiving their first loading dose of three intravitreal anti-VEFG-injections at the Department of Ophthalmology, Helsinki University Central Hospital, Finland, between January 2007 and December 2008 were analyzed retrospectively. The DNA samples were collected to further study the factors affecting treatment response.

Methods:

Clinical records, smoking history, optical coherence tomographies (OCTs), and angiographies of 96 bevacizumab-treated exudative AMD patients were analyzed and blood DNA was collected. Based on the disappearance of intra- or subretinal fluid in OCT patients were graded as responders, partial responders or nonresponders after three initial treatment visits and a median time of 3.5 months. The associations between SNPs, lesion characteristics, and anatomical and functional treatment response were analyzed.

Results:

IL-8 promoter polymorphism -251A/T was significantly associated with persisting fluid in OCT. The A allele was more frequent in nonresponders than in responders (P = 0.033). In multivariate modeling the AA genotype of -251A/T (P = 0.043), and occult (P = 0.042) or predominantly classic (P = 0.040) lesions predicted poorer outcome. Visual acuity (VA) change was better in responders than in nonresponders (P = 0.006). Baseline lesion size (P = 0.006) and retinal cysts after the treatment (P < 0.001) correlated with less VA gain.

Conclusions:

The genotype AA of interleukin-8 promoter polymorphism -251A/T was associated with persisting intra- or subretinal fluid in exudative age-related macular degeneration patients after the initial treatment with intravitreal bevacizumab. Interleukin-8 seems to modulate the response to anti-VEGF therapy at least during the first months of the treatment.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy